According to a recent LinkedIn post from RIVANNA, the company is showcasing its Accuro 3S platform at the SOAP 2026 meeting in Montreal. The post describes Accuro 3S as an FDA‑cleared, AI‑enabled real‑time guidance system designed to assist neuraxial anesthesia with automated landmark detection and continuous needle tip tracking.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also notes that Accuro 3S incorporates a Dual‑Array probe for real‑time midline access and a stabilizing drape aimed at improving tactile needle control. This emphasis on workflow and accuracy suggests RIVANNA is positioning the platform as a tool to enhance safety and consistency in obstetric and neuraxial anesthesia.
As shared in the post, RIVANNA’s initial Pioneer Partner program is now full, and the company is opening early access to a limited group of 25 “Trailblazer” sites. These sites are expected to generate real‑world outcome data that could be important in demonstrating clinical value, informing reimbursement discussions, and supporting broader adoption.
For investors, the focus on AI‑enabled image guidance and structured early‑access cohorts points to a strategy centered on evidence generation and scalable deployment in hospital settings. If Accuro 3S can deliver improved outcomes and workflow efficiency, it may strengthen RIVANNA’s competitive position in the medtech segment for anesthesia guidance and support future revenue growth through expanded clinical integration.